Symbols / CELC Stock $122.96 -7.47% Celcuity Inc.

Healthcare • Biotechnology • United States • NCM
CELC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Brian F. Sullivan
Exch · Country NCM · United States
Market Cap 6.00B
Enterprise Value 5.93B
Income -192.89M
Sales —
FCF (ttm) -110.84M
Book/sh 1.11
Cash/sh 7.94
Employees 155
Insider 10d —
IPO Sep 20, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 166.16
PEG —
P/S —
P/B 111.07
P/C —
EV/EBITDA -31.83
EV/Sales —
Quick Ratio 11.65
Current Ratio 12.31
Debt/Eq 604.28
LT Debt/Eq —
EPS (ttm) -3.90
EPS next Y 0.74
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-14
ROA -37.12%
ROE -275.17%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 48.77M
Shs Float 26.81M
Insider Own 10.01%
Instit Own 101.30%
Short Float 29.45%
Short Ratio 8.00
Short Interest 9.56M
52W High 151.02
vs 52W High -18.58%
52W Low 11.09
vs 52W Low 1,009.25%
Beta 0.09
Impl. Vol. 0.78%
Rel Volume 2.04
Avg Volume 938.89K
Volume 1.92M
Target (mean) $169.00
Tgt Median $165.00
Tgt Low $157.00
Tgt High $189.00
# Analysts 11
Recom Strong_buy
Prev Close $132.88
Price $122.96
Change -7.47%
About

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$169.00
Mean price target
2. Current target
$122.96
Latest analyst target
3. DCF / Fair value
$-40.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$122.96
Low
$157.00
High
$189.00
Mean
$169.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-18 main HC Wainwright & Co. Buy → Buy $185
2026-05-15 main Wells Fargo Overweight → Overweight $183
2026-05-15 reit Needham Buy → Buy $157
2026-05-04 main Citizens Market Outperform → Market Outperform $160
2026-05-04 main Guggenheim Buy → Buy $165
2026-05-04 up HC Wainwright & Co. Neutral → Buy $165
2026-05-04 main Needham Buy → Buy $157
2026-04-27 init Citizens — → Market Outperform $150
2026-03-26 main Stifel Buy → Buy $125
2026-03-26 reit Needham Buy → Buy $122
2026-03-17 reit Needham Buy → Buy $122
2026-03-10 main Needham Buy → Buy $122
2025-12-12 init Wells Fargo — → Overweight $126
2025-12-02 main Jefferies Buy → Buy $134
2025-11-18 init Wolfe Research — → Outperform $110
2025-11-17 down HC Wainwright & Co. Buy → Neutral $94
2025-11-13 main Craig-Hallum Buy → Buy $108
2025-11-13 main Stifel Buy → Buy $115
2025-10-22 main HC Wainwright & Co. Buy → Buy $77
2025-10-20 reit Needham Buy → Buy $70
News
RSS: Latest CELC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-19 BULLER RICHARD E Director — 1,029 $0.00 $0
2026-05-04 BULLER RICHARD E Director — 9,000 $137.00 $1,264,181
2026-05-04 DALVEY DAVID F Director — 25,000 $140.68 $3,517,000
2026-05-04 BULLER RICHARD E Director — 9,000 $5.10 $45,900
2026-04-09 NIGON RICHARD J Director — 10,000 $0.00 $0
2026-03-31 BULLER RICHARD E Director — 3,000 $110.11 $330,804
2026-03-31 BULLER RICHARD E Director — 3,000 $5.10 $15,300
2026-02-11 ROMP CHARLES R Director — 215 $0.00 $0
2026-01-27 DALVEY DAVID F Director — 20,000 $120.03 $2,400,538
2025-12-15 NIGON RICHARD J Director — 19,975 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
172.19
+52.02%
113.27
+71.02%
66.23
+68.14%
39.39
Research And Development
145.00
+39.15%
104.20
+71.97%
60.59
+71.71%
35.29
Selling General And Administration
27.20
+200.06%
9.06
+60.81%
5.64
+37.42%
4.10
General And Administrative Expense
27.20
+200.06%
9.06
+60.81%
5.64
+37.42%
4.10
Other Gand A
27.20
+200.06%
9.06
+60.81%
5.64
+37.42%
4.10
Total Expenses
172.19
+52.02%
113.27
+71.02%
66.23
+68.14%
39.39
Operating Income
-172.19
-52.02%
-113.27
-71.02%
-66.23
-68.14%
-39.39
Total Operating Income As Reported
-172.19
-52.02%
-113.27
-71.02%
-66.23
-68.14%
-39.39
EBITDA
-159.73
-57.57%
-101.37
-73.85%
-58.31
-53.23%
-38.05
Normalized EBITDA
-159.73
-57.57%
-101.37
-73.85%
-58.31
-53.23%
-38.05
Reconciled Depreciation
0.17
+28.46%
0.13
-8.95%
0.14
-32.31%
0.21
EBIT
-159.89
-57.53%
-101.50
-73.64%
-58.45
-52.76%
-38.26
Total Unusual Items
—
—
—
0.00
Total Unusual Items Excluding Goodwill
—
—
—
0.00
Special Income Charges
—
—
—
0.00
Net Income
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Pretax Income
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Net Non Operating Interest Income Expense
-4.85
-425.94%
1.49
-39.30%
2.45
+350.39%
-0.98
Interest Expense Non Operating
17.15
+66.81%
10.28
+93.00%
5.33
+152.90%
2.11
Net Interest Income
-4.85
-425.94%
1.49
-39.30%
2.45
+350.39%
-0.98
Interest Expense
17.15
+66.81%
10.28
+93.00%
5.33
+152.90%
2.11
Interest Income Non Operating
12.30
+4.50%
11.77
+51.31%
7.78
+590.02%
1.13
Interest Income
12.30
+4.50%
11.77
+51.31%
7.78
+590.02%
1.13
Other Income Expense
—
—
—
—
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Net Income From Continuing Operation Net Minority Interest
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Net Income From Continuing And Discontinued Operation
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Net Income Continuous Operations
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Normalized Income
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Net Income Common Stockholders
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Diluted EPS
-3.79
-33.92%
-2.83
-5.20%
-2.69
-1.89%
-2.64
Basic EPS
-3.79
-33.92%
-2.83
-5.20%
-2.69
-1.89%
-2.64
Basic Average Shares
46.76
+18.53%
39.45
+66.60%
23.68
+53.58%
15.42
Diluted Average Shares
46.76
+18.53%
39.45
+66.60%
23.68
+53.58%
15.42
Diluted NI Availto Com Stockholders
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Gain On Sale Of PPE
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
466.56
+90.34%
245.12
+28.19%
191.22
+8.83%
175.70
Current Assets
465.66
+90.40%
244.57
+28.32%
190.59
+8.79%
175.19
Cash Cash Equivalents And Short Term Investments
441.50
+87.79%
235.10
+30.19%
180.58
+7.12%
168.59
Cash And Cash Equivalents
165.70
+635.97%
22.52
-26.57%
30.66
+24.79%
24.57
Other Short Term Investments
275.79
+29.73%
212.59
+41.80%
149.92
+4.10%
144.02
Receivables
—
1.60
+98.62%
0.81
0.00
Other Receivables
—
1.60
+98.62%
0.81
—
Taxes Receivable
—
—
—
0.20
Prepaid Assets
18.90
+179.15%
6.77
-24.12%
8.92
+42.69%
6.25
Current Deferred Assets
—
—
—
0.03
Other Current Assets
5.27
+95.18%
2.70
+858.90%
0.28
-19.86%
0.35
Total Non Current Assets
0.90
+62.86%
0.55
-12.21%
0.63
+24.13%
0.51
Net PPE
0.55
-0.36%
0.55
-12.21%
0.63
+24.13%
0.51
Gross PPE
2.71
+6.49%
2.54
+2.14%
2.49
+11.91%
2.23
Accumulated Depreciation
-2.16
-8.38%
-1.99
-6.98%
-1.86
-8.30%
-1.72
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
2.35
+16.25%
2.02
+13.24%
1.79
+6.63%
1.68
Other Properties
0.05
-76.39%
0.22
-46.00%
0.40
+62.43%
0.25
Leases
0.30
+0.33%
0.30
+0.14%
0.30
+0.00%
0.30
Other Non Current Assets
0.35
—
—
—
Total Liabilities Net Minority Interest
366.00
+182.62%
129.50
+151.71%
51.45
+22.72%
41.93
Current Liabilities
44.15
+39.18%
31.72
+123.58%
14.19
+106.19%
6.88
Payables And Accrued Expenses
35.76
+30.23%
27.46
+125.39%
12.18
+113.02%
5.72
Payables
6.41
-31.59%
9.37
+84.49%
5.08
+93.25%
2.63
Accounts Payable
6.41
-31.59%
9.37
+84.49%
5.08
+93.25%
2.63
Current Accrued Expenses
29.35
+62.23%
18.09
+154.61%
7.11
+129.82%
3.09
Pensionand Other Post Retirement Benefit Plans Current
8.34
+103.76%
4.09
+124.74%
1.82
+88.06%
0.97
Current Debt And Capital Lease Obligation
0.05
-68.60%
0.17
-7.00%
0.18
-4.76%
0.19
Current Capital Lease Obligation
0.05
-68.60%
0.17
-7.00%
0.18
-4.76%
0.19
Total Non Current Liabilities Net Minority Interest
321.85
+229.15%
97.78
+162.42%
37.26
+6.33%
35.04
Long Term Debt And Capital Lease Obligation
321.85
+229.15%
97.78
+162.42%
37.26
+6.33%
35.04
Long Term Debt
321.85
+229.34%
97.73
+163.87%
37.04
+5.87%
34.98
Long Term Capital Lease Obligation
0.00
-100.00%
0.05
-76.10%
0.23
+270.35%
0.06
Stockholders Equity
100.56
-13.03%
115.62
-17.28%
139.77
+4.48%
133.77
Common Stock Equity
100.56
-13.03%
115.62
-17.28%
139.77
+4.48%
133.77
Capital Stock
0.05
+29.73%
0.04
+40.36%
0.03
+15.67%
0.02
Common Stock
0.05
+29.73%
0.04
+45.06%
0.03
+17.72%
0.02
Preferred Stock
0.00
0.00
-100.00%
0.00
-23.82%
0.00
Share Issued
48.24
+29.89%
37.14
+45.63%
25.51
+17.72%
21.67
Ordinary Shares Number
48.24
+29.89%
37.14
+45.63%
25.51
+17.72%
21.67
Additional Paid In Capital
549.40
+41.80%
387.44
+29.22%
299.82
+30.33%
230.05
Retained Earnings
-448.90
-65.12%
-271.86
-69.83%
-160.08
-66.23%
-96.30
Total Equity Gross Minority Interest
100.56
-13.03%
115.62
-17.28%
139.77
+4.48%
133.77
Total Capitalization
422.41
+97.99%
213.35
+20.67%
176.80
+4.77%
168.75
Working Capital
421.51
+98.03%
212.85
+20.66%
176.40
+4.81%
168.31
Invested Capital
422.41
+97.99%
213.35
+20.67%
176.80
+4.77%
168.75
Total Debt
321.90
+228.63%
97.95
+161.58%
37.45
+6.27%
35.24
Net Debt
156.15
+107.61%
75.21
+1080.23%
6.37
-38.79%
10.41
Capital Lease Obligations
0.05
-76.11%
0.23
-45.00%
0.41
+61.00%
0.26
Net Tangible Assets
100.56
-13.03%
115.62
-17.28%
139.77
+4.48%
133.77
Tangible Book Value
100.56
-13.03%
115.62
-17.28%
139.77
+4.48%
133.77
Interest Payable
3.38
—
—
—
Preferred Stock Equity
—
0.00
-62.76%
0.00
-23.82%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-153.28
-83.64%
-83.47
-55.11%
-53.81
-49.44%
-36.01
Cash Flow From Continuing Operating Activities
-153.28
-83.64%
-83.47
-55.11%
-53.81
-49.44%
-36.01
Net Income From Continuing Operations
-177.04
-58.39%
-111.78
-75.26%
-63.78
-57.99%
-40.37
Depreciation Amortization Depletion
0.17
+28.46%
0.13
-8.95%
0.14
-32.31%
0.21
Depreciation
0.17
+28.46%
0.13
-8.95%
0.14
-32.31%
0.21
Depreciation And Amortization
0.17
+28.46%
0.13
-8.95%
0.14
-32.31%
0.21
Other Non Cash Items
4.86
+70.97%
2.85
+167.58%
1.06
+50.89%
0.70
Stock Based Compensation
21.38
+206.00%
6.99
+42.57%
4.90
+5.68%
4.64
Operating Gains Losses
—
—
—
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
-2.65
-114.45%
18.35
+375.44%
3.86
+423.80%
-1.19
Change In Receivables
—
—
—
0.10
Change In Prepaid Assets
-12.13
-508.17%
-1.99
—
-5.62
Change In Payables And Accrued Expense
12.47
-29.06%
17.57
+140.81%
7.30
+68.36%
4.33
Change In Accrued Expense
15.51
+16.96%
13.26
+172.40%
4.87
+49.41%
3.26
Change In Payable
-3.04
-170.44%
4.32
+77.57%
2.43
+125.67%
1.08
Change In Account Payable
-3.04
-170.44%
4.32
+77.57%
2.43
+125.67%
1.08
Change In Other Working Capital
—
—
—
—
Change In Other Current Assets
-2.99
-207.98%
2.77
+180.57%
-3.44
+37.79%
-5.53
Investing Cash Flow
-64.08
-1.61%
-63.07
-1159.31%
-5.01
+96.52%
-144.03
Cash Flow From Continuing Investing Activities
-64.08
-1.61%
-63.07
-1159.31%
-5.01
+96.52%
-144.03
Net PPE Purchase And Sale
-0.25
+0.40%
-0.25
-156.03%
-0.10
+38.50%
-0.16
Purchase Of PPE
-0.25
+0.40%
-0.25
-156.03%
-0.10
+38.50%
-0.16
Sale Of PPE
—
—
—
0.00
Capital Expenditure
-0.25
+0.40%
-0.25
-156.03%
-0.10
+38.50%
-0.16
Net Investment Purchase And Sale
-63.84
-1.62%
-62.82
-1179.26%
-4.91
+96.59%
-143.87
Purchase Of Investment
-396.34
+43.79%
-705.16
-124.20%
-314.53
-118.61%
-143.87
Sale Of Investment
332.51
-48.24%
642.35
+107.47%
309.61
0.00
Financing Cash Flow
360.55
+160.54%
138.39
+113.19%
64.91
-46.05%
120.33
Cash Flow From Continuing Financing Activities
360.55
+160.54%
138.39
+113.19%
64.91
-46.05%
120.33
Net Issuance Payments Of Debt
222.75
+276.10%
59.23
+2418474.85%
-0.00
-100.01%
19.50
Issuance Of Debt
222.75
+276.10%
59.23
0.00
-100.00%
19.51
Repayment Of Debt
—
0.00
+100.00%
-0.00
+58.14%
-0.01
Long Term Debt Issuance
222.75
+276.10%
59.23
0.00
-100.00%
19.51
Long Term Debt Payments
—
0.00
+100.00%
-0.00
+58.14%
-0.01
Net Long Term Debt Issuance
222.75
+276.10%
59.23
+2418474.85%
-0.00
-100.01%
19.50
Net Common Stock Issuance
91.59
+43.99%
63.61
+340.77%
14.43
-85.64%
100.50
Proceeds From Stock Option Exercised
46.26
+193.10%
15.78
-68.77%
50.53
+15490.26%
0.32
Net Other Financing Charges
-0.05
+79.82%
-0.23
-369.90%
-0.05
—
Changes In Cash
143.19
+1857.34%
-8.15
-233.77%
6.09
+110.20%
-59.71
Beginning Cash Position
22.52
-26.57%
30.66
+24.79%
24.57
-70.85%
84.29
End Cash Position
165.70
+635.97%
22.52
-26.57%
30.66
+24.79%
24.57
Free Cash Flow
-153.53
-83.39%
-83.72
-55.29%
-53.91
-49.06%
-36.17
Interest Paid Supplemental Data
10.35
+36.41%
7.59
+131.70%
3.27
+160.82%
1.26
Change In Interest Payable
—
—
—
-0.14
Common Stock Issuance
91.59
+43.99%
63.61
+340.77%
14.43
-85.64%
100.50
Issuance Of Capital Stock
91.59
+43.99%
63.61
+340.77%
14.43
-85.64%
100.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category